Lecture 1 part 4 Flashcards
Therapeutic Drug Monitoring (TDM)
Boundaries between sub-therapeutic,therapeutic and toxic drug concentrations are not absolute
Factors that cause variability in (Cp) and pharmacologic response:
Individual ability to _________ and eliminate drug (genetics)
Drug _________ variability
Disease state
Physiologic states ( extremes of ________, obesity)
Drug interactions
metabolize
absorption
age
Therapeutic Drug Monitoring (TDM)
Clinical PK applied to TDM for very potent drugs (those with a ___________ therapeutic range)
TDM: the use of plasma drug concentration data to develop safe and effective drug regimens
IF performed properly, the achievement of therapeutic concentrations of a drug will be more rapidly and safely than with the empiric dose changes
TDM along with the observation of clinical effects: the safest approach to optimal drug therapy
Drugs frequently monitored: aminoglycosides, anticonvulsants, and those used in cancer chemotherapy
narrow
Process of making drug dosing decisions
A diagnosis is made, A drug is selected,Dosage schedule is designed to reach a target plasma concentration, Drug is administered,Patient assessments are performed,Drug concentrations are determined,A PK model applied and clinical judgment is used
MTC: Minimum Toxic Concentration
MEC: Minimum Effective Concentration; barely produce an effect
_________: reflects the minimum concentration of drug needed at the receptor to produce the desired pharmacological effect
MEC
MTC: The concentration needed to just barely produce a toxic effect
With Iv bolus injection there is an immediate onset of action
With IV infusion there is a steady state concentration
PK is the science of the kinetics of ADME, whereas ______________considers the applications of PK to drug therapy
clinical PK
The quantitative measurement of drug concentrations in the plasma is important to obtain relevant data of systemic _____________
drug exposure
The plasma drug concentration versus time profile provides:
The basic data from which various PK models can be developed that predict the time course of drug action, or adverse response
Enables the development of individualized therapeutic dosage regimens